Skip to content

About us

eCounsel group

A boutique firm with unparalleled expertise in business and technology. We have good command of industrial ecology and legal practice, and have undertaken highly regarded cases. Because the small business scope, we pay more emphasis on effectiveness and efficiency, and choose clients with deliberation. The managing partner not only has extensive experiences in various legal issues more over than 20 years, but invests and manages several technology companies. In addition, he always checks each case rigorously. Clients’ business objectives are our primary focus. To achieve the same in the most cost-effective fashion trumps all seemingly sophisticated legal discussions.

Americans Struggle With High Drug Prices

2016 - 01 - 12

For many Americans, going to doctors and getting prescription drugs can cause bankruptcy.

對很多美國人來說,看病買藥,是會破產的。從以下華爾街日報文章,可以略窺美國人沒錢買藥的心酸。摘譯如下:

Patients Struggle With High Drug Prices

“even patients with insurance and comfortable incomes are sometimes forced to make hard choices – tapping savings, taking on new debt or even forgoing treatment.”
即便是那些擁有醫療保險和安逸收入的病人,(為了買藥)有時都會被迫作出痛苦的決定:動用積蓄、舉債、甚至放棄治療

“A quarter of U.S. prescription-drug users said it was difficult to afford them”
美國拿處方箋的病人中,有四分之一表示很難買得起那些藥

“Drug prices are one of the main drivers of insurance-premium increases… Lowering patients’ share of expensive drugs’ cost would mean even higher premiums…”
藥價是使得保險費被調高的主要原因之一… 為了降低病人對高價藥之負擔,自然需要更高的保險費…

看看別人,想想自己
1. 我們的醫藥已達先進國家水準
2. 我們的健保賠付項目包山包海
3. 台灣的人民隨時隨地都能看病
4. 台灣病人的拿藥比例世界最高
5. 病人之部分負擔額度全球最低

我們的健保當然需要改革。在這樣的制度滋養下,台灣病人的財務負擔之痛苦以全球觀點而言的確低到難以想像、而同時醫護人員在金錢誘因不足的健保賠付基礎上又承擔過高之道德與法律責任。永遠爭論不休的原廠藥(如果要討論,務必請區隔專利過期否)與同成分同劑量同劑型之學名藥的支付標準與健保局之緊箍咒(藥價調查),更是我未來會努力關切的課題。

(編按:第4, 5兩點是基於本所主持律師三年之前所作的研究,數據取自OECD國家之統計報告,如果有誤,歡迎賜正)

Recommended article 

Market Outlook for Blue-Chip Debt Worsening

Issuing bond or applying loans from bank are common ways of financing. But the former is a direct loan from investors, how investors view the default risk will reflect on the interest rates. Continue reading

Internal Controls and Compliance Regulations in Taiwan

In Taiwan, Criteria for Establishment of Internal Control Systems by Public Companies is the most significant regulation regarding internal controls. 在台灣,最主要的內部控制規範是「公開發行公司建立內部控制制度處理準則」,本準則是依據證券交易法的規定授權,而由前主管機關「財政部證券暨期貨管理委員會」(現已改為行政院金融監督管理委員會)於民國91年11月18日所發布的,目前最新的條文則是於民國96年7月17日修正過後的版本。 由於COSO報告與美國的沙賓法案對於全世界的影響力極為廣大深遠,我國當然也不可能置身事外而不受到美國的影響,大致上,我國內控處理準則的三大目標與五大要素都是符合COSO報告所提出的架構,為了因應許多企業弊案而生的沙賓法案也是我國規範的最佳參考對象。 我國的內控處理準則並非如大陸一樣是以上市公司為施行對象,而是範圍稍微廣一點的公開發行公司1,而依據該處理準則的定義,內部控制是指:「由經理人所設計,經董事會所通過,並由董事會、經理人及其他員工執行之管理過程,其目的在於促進公司的健全經營,以合理確保下列目標之達成:一、營運之效果及效率。二、財務報導之可靠性。三、相關法令之遵循。」COSO報告的影響力可見一斑。 雖然美、中、台的內部控制制度應是系出同源,下我們仍然想要從我國的內控處理準則裡面找出一些蛛絲馬跡,看看在一些重要的制度方面,台灣是否跟得上世界潮流? 參考資料: 1. 首次辦理公開發行之公司必須建立有效的內部控制制度,並經會計師審查認為無重大缺失後才能申請公開發行。

Hong Kong: Say Goodbye to Good Old Days

When Hong Kong returned in 1997, Chinese government made a promise to maintain its social and political status for 50 years. Now it’s all different. Continue reading